Health Care·Biotechnology·$5.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.82 | N/A | -14.53% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.82 | N/A | -14.53% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed concern over recent performance but remains focused on future strategies. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized a commitment to long-term strategies despite current setbacks.
The earnings report indicates that Rhythm Pharmaceuticals is struggling with its profitability, as reflected in the negative EPS. The stock's 7.69% decline suggests that investors are reacting negatively to the missed expectations and lack of revenue information. The management's defensive tone indicates ongoing challenges, which may impact investor confidence moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Nov 3, 2025